nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2B6—Sorafenib—liver cancer	0.0927	0.223	CbGbCtD
Paroxetine—CYP2C8—Sorafenib—liver cancer	0.0702	0.169	CbGbCtD
Paroxetine—CYP2B6—Doxorubicin—liver cancer	0.0563	0.135	CbGbCtD
Paroxetine—CYP2C9—Sorafenib—liver cancer	0.049	0.118	CbGbCtD
Paroxetine—ABCB1—Sorafenib—liver cancer	0.0475	0.114	CbGbCtD
Paroxetine—CYP2D6—Sorafenib—liver cancer	0.0448	0.108	CbGbCtD
Paroxetine—ABCB1—Doxorubicin—liver cancer	0.0288	0.0693	CbGbCtD
Paroxetine—CYP2D6—Doxorubicin—liver cancer	0.0272	0.0653	CbGbCtD
Paroxetine—Dizziness—Sorafenib—liver cancer	0.000342	0.000794	CcSEcCtD
Paroxetine—Mood swings—Doxorubicin—liver cancer	0.000341	0.000791	CcSEcCtD
Paroxetine—Ataxia—Doxorubicin—liver cancer	0.000338	0.000786	CcSEcCtD
Paroxetine—Asthma—Epirubicin—liver cancer	0.000336	0.00078	CcSEcCtD
Paroxetine—Influenza—Epirubicin—liver cancer	0.000336	0.00078	CcSEcCtD
Paroxetine—Dysphagia—Epirubicin—liver cancer	0.000336	0.00078	CcSEcCtD
Paroxetine—Dehydration—Doxorubicin—liver cancer	0.000335	0.000777	CcSEcCtD
Paroxetine—Eosinophilia—Epirubicin—liver cancer	0.000333	0.000773	CcSEcCtD
Paroxetine—Liver function test abnormal—Doxorubicin—liver cancer	0.000332	0.000771	CcSEcCtD
Paroxetine—Dry skin—Doxorubicin—liver cancer	0.00033	0.000766	CcSEcCtD
Paroxetine—Pancreatitis—Epirubicin—liver cancer	0.00033	0.000765	CcSEcCtD
Paroxetine—Vomiting—Sorafenib—liver cancer	0.000329	0.000764	CcSEcCtD
Paroxetine—Orthostatic hypotension—Doxorubicin—liver cancer	0.000329	0.000763	CcSEcCtD
Paroxetine—Hypokalaemia—Doxorubicin—liver cancer	0.000327	0.00076	CcSEcCtD
Paroxetine—Angina pectoris—Epirubicin—liver cancer	0.000327	0.00076	CcSEcCtD
Paroxetine—Rash—Sorafenib—liver cancer	0.000326	0.000757	CcSEcCtD
Paroxetine—Dermatitis—Sorafenib—liver cancer	0.000326	0.000756	CcSEcCtD
Paroxetine—Breast disorder—Doxorubicin—liver cancer	0.000325	0.000755	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000324	0.000752	CcSEcCtD
Paroxetine—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000324	0.000752	CcSEcCtD
Paroxetine—Headache—Sorafenib—liver cancer	0.000324	0.000752	CcSEcCtD
Paroxetine—Bronchitis—Epirubicin—liver cancer	0.000323	0.000751	CcSEcCtD
Paroxetine—Nasopharyngitis—Doxorubicin—liver cancer	0.000322	0.000747	CcSEcCtD
Paroxetine—Pancytopenia—Epirubicin—liver cancer	0.000319	0.000741	CcSEcCtD
Paroxetine—Gastritis—Doxorubicin—liver cancer	0.000318	0.000739	CcSEcCtD
Paroxetine—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000317	0.000737	CcSEcCtD
Paroxetine—Muscular weakness—Doxorubicin—liver cancer	0.000317	0.000737	CcSEcCtD
Paroxetine—Dysuria—Epirubicin—liver cancer	0.000314	0.00073	CcSEcCtD
Paroxetine—Asthma—Doxorubicin—liver cancer	0.000311	0.000722	CcSEcCtD
Paroxetine—Dysphagia—Doxorubicin—liver cancer	0.000311	0.000722	CcSEcCtD
Paroxetine—Influenza—Doxorubicin—liver cancer	0.000311	0.000722	CcSEcCtD
Paroxetine—Pollakiuria—Epirubicin—liver cancer	0.00031	0.000721	CcSEcCtD
Paroxetine—Eosinophilia—Doxorubicin—liver cancer	0.000308	0.000715	CcSEcCtD
Paroxetine—Nausea—Sorafenib—liver cancer	0.000307	0.000713	CcSEcCtD
Paroxetine—Photosensitivity reaction—Epirubicin—liver cancer	0.000307	0.000712	CcSEcCtD
Paroxetine—Weight increased—Epirubicin—liver cancer	0.000306	0.00071	CcSEcCtD
Paroxetine—Pancreatitis—Doxorubicin—liver cancer	0.000305	0.000708	CcSEcCtD
Paroxetine—Weight decreased—Epirubicin—liver cancer	0.000304	0.000706	CcSEcCtD
Paroxetine—Hyperglycaemia—Epirubicin—liver cancer	0.000303	0.000704	CcSEcCtD
Paroxetine—Angina pectoris—Doxorubicin—liver cancer	0.000303	0.000703	CcSEcCtD
Paroxetine—Pneumonia—Epirubicin—liver cancer	0.000301	0.0007	CcSEcCtD
Paroxetine—Drowsiness—Epirubicin—liver cancer	0.0003	0.000696	CcSEcCtD
Paroxetine—Bronchitis—Doxorubicin—liver cancer	0.000299	0.000694	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000297	0.00069	CcSEcCtD
Paroxetine—Pancytopenia—Doxorubicin—liver cancer	0.000295	0.000686	CcSEcCtD
Paroxetine—Neuropathy peripheral—Epirubicin—liver cancer	0.000294	0.000682	CcSEcCtD
Paroxetine—Stomatitis—Epirubicin—liver cancer	0.000292	0.000678	CcSEcCtD
Paroxetine—Jaundice—Epirubicin—liver cancer	0.000292	0.000678	CcSEcCtD
Paroxetine—Conjunctivitis—Epirubicin—liver cancer	0.000291	0.000676	CcSEcCtD
Paroxetine—Urinary tract infection—Epirubicin—liver cancer	0.000291	0.000676	CcSEcCtD
Paroxetine—Dysuria—Doxorubicin—liver cancer	0.000291	0.000675	CcSEcCtD
Paroxetine—Sweating—Epirubicin—liver cancer	0.000287	0.000667	CcSEcCtD
Paroxetine—Pollakiuria—Doxorubicin—liver cancer	0.000287	0.000667	CcSEcCtD
Paroxetine—Haematuria—Epirubicin—liver cancer	0.000286	0.000663	CcSEcCtD
Paroxetine—Photosensitivity reaction—Doxorubicin—liver cancer	0.000284	0.000659	CcSEcCtD
Paroxetine—Hepatobiliary disease—Epirubicin—liver cancer	0.000283	0.000658	CcSEcCtD
Paroxetine—Weight increased—Doxorubicin—liver cancer	0.000283	0.000657	CcSEcCtD
Paroxetine—Epistaxis—Epirubicin—liver cancer	0.000283	0.000656	CcSEcCtD
Paroxetine—Weight decreased—Doxorubicin—liver cancer	0.000281	0.000653	CcSEcCtD
Paroxetine—Sinusitis—Epirubicin—liver cancer	0.000281	0.000653	CcSEcCtD
Paroxetine—Hyperglycaemia—Doxorubicin—liver cancer	0.000281	0.000651	CcSEcCtD
Paroxetine—Agranulocytosis—Epirubicin—liver cancer	0.00028	0.000649	CcSEcCtD
Paroxetine—Pneumonia—Doxorubicin—liver cancer	0.000279	0.000648	CcSEcCtD
Paroxetine—Drowsiness—Doxorubicin—liver cancer	0.000277	0.000644	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000275	0.000638	CcSEcCtD
Paroxetine—Bradycardia—Epirubicin—liver cancer	0.000274	0.000636	CcSEcCtD
Paroxetine—Neuropathy peripheral—Doxorubicin—liver cancer	0.000272	0.000631	CcSEcCtD
Paroxetine—Haemoglobin—Epirubicin—liver cancer	0.00027	0.000628	CcSEcCtD
Paroxetine—Stomatitis—Doxorubicin—liver cancer	0.00027	0.000628	CcSEcCtD
Paroxetine—Jaundice—Doxorubicin—liver cancer	0.00027	0.000628	CcSEcCtD
Paroxetine—Rhinitis—Epirubicin—liver cancer	0.00027	0.000626	CcSEcCtD
Paroxetine—Urinary tract infection—Doxorubicin—liver cancer	0.00027	0.000626	CcSEcCtD
Paroxetine—Conjunctivitis—Doxorubicin—liver cancer	0.00027	0.000626	CcSEcCtD
Paroxetine—Haemorrhage—Epirubicin—liver cancer	0.000269	0.000625	CcSEcCtD
Paroxetine—Hepatitis—Epirubicin—liver cancer	0.000269	0.000625	CcSEcCtD
Paroxetine—Hypoaesthesia—Epirubicin—liver cancer	0.000268	0.000622	CcSEcCtD
Paroxetine—Pharyngitis—Epirubicin—liver cancer	0.000267	0.00062	CcSEcCtD
Paroxetine—Sweating—Doxorubicin—liver cancer	0.000266	0.000617	CcSEcCtD
Paroxetine—Oedema peripheral—Epirubicin—liver cancer	0.000265	0.000615	CcSEcCtD
Paroxetine—Haematuria—Doxorubicin—liver cancer	0.000264	0.000614	CcSEcCtD
Paroxetine—Connective tissue disorder—Epirubicin—liver cancer	0.000264	0.000614	CcSEcCtD
Paroxetine—Hepatobiliary disease—Doxorubicin—liver cancer	0.000262	0.000609	CcSEcCtD
Paroxetine—Epistaxis—Doxorubicin—liver cancer	0.000262	0.000607	CcSEcCtD
Paroxetine—Sinusitis—Doxorubicin—liver cancer	0.00026	0.000604	CcSEcCtD
Paroxetine—Visual impairment—Epirubicin—liver cancer	0.000259	0.000602	CcSEcCtD
Paroxetine—Agranulocytosis—Doxorubicin—liver cancer	0.000259	0.000601	CcSEcCtD
Paroxetine—Erythema multiforme—Epirubicin—liver cancer	0.000254	0.000591	CcSEcCtD
Paroxetine—Bradycardia—Doxorubicin—liver cancer	0.000253	0.000588	CcSEcCtD
Paroxetine—Eye disorder—Epirubicin—liver cancer	0.000251	0.000584	CcSEcCtD
Paroxetine—Tinnitus—Epirubicin—liver cancer	0.000251	0.000582	CcSEcCtD
Paroxetine—Haemoglobin—Doxorubicin—liver cancer	0.00025	0.000581	CcSEcCtD
Paroxetine—Flushing—Epirubicin—liver cancer	0.00025	0.00058	CcSEcCtD
Paroxetine—Cardiac disorder—Epirubicin—liver cancer	0.00025	0.00058	CcSEcCtD
Paroxetine—Rhinitis—Doxorubicin—liver cancer	0.00025	0.000579	CcSEcCtD
Paroxetine—Haemorrhage—Doxorubicin—liver cancer	0.000249	0.000578	CcSEcCtD
Paroxetine—Hepatitis—Doxorubicin—liver cancer	0.000249	0.000578	CcSEcCtD
Paroxetine—Hypoaesthesia—Doxorubicin—liver cancer	0.000248	0.000575	CcSEcCtD
Paroxetine—Pharyngitis—Doxorubicin—liver cancer	0.000247	0.000574	CcSEcCtD
Paroxetine—Oedema peripheral—Doxorubicin—liver cancer	0.000245	0.000569	CcSEcCtD
Paroxetine—Connective tissue disorder—Doxorubicin—liver cancer	0.000245	0.000568	CcSEcCtD
Paroxetine—Angiopathy—Epirubicin—liver cancer	0.000244	0.000567	CcSEcCtD
Paroxetine—Immune system disorder—Epirubicin—liver cancer	0.000243	0.000564	CcSEcCtD
Paroxetine—Mediastinal disorder—Epirubicin—liver cancer	0.000242	0.000563	CcSEcCtD
Paroxetine—Chills—Epirubicin—liver cancer	0.000241	0.00056	CcSEcCtD
Paroxetine—Arrhythmia—Epirubicin—liver cancer	0.00024	0.000558	CcSEcCtD
Paroxetine—Visual impairment—Doxorubicin—liver cancer	0.00024	0.000557	CcSEcCtD
Paroxetine—Alopecia—Epirubicin—liver cancer	0.000238	0.000552	CcSEcCtD
Paroxetine—Mental disorder—Epirubicin—liver cancer	0.000236	0.000547	CcSEcCtD
Paroxetine—Erythema multiforme—Doxorubicin—liver cancer	0.000235	0.000546	CcSEcCtD
Paroxetine—Erythema—Epirubicin—liver cancer	0.000234	0.000544	CcSEcCtD
Paroxetine—Malnutrition—Epirubicin—liver cancer	0.000234	0.000544	CcSEcCtD
Paroxetine—Eye disorder—Doxorubicin—liver cancer	0.000233	0.00054	CcSEcCtD
Paroxetine—Tinnitus—Doxorubicin—liver cancer	0.000232	0.000539	CcSEcCtD
Paroxetine—Cardiac disorder—Doxorubicin—liver cancer	0.000231	0.000536	CcSEcCtD
Paroxetine—Flushing—Doxorubicin—liver cancer	0.000231	0.000536	CcSEcCtD
Paroxetine—Flatulence—Epirubicin—liver cancer	0.000231	0.000536	CcSEcCtD
Paroxetine—Tension—Epirubicin—liver cancer	0.00023	0.000534	CcSEcCtD
Paroxetine—Dysgeusia—Epirubicin—liver cancer	0.000229	0.000533	CcSEcCtD
Paroxetine—Nervousness—Epirubicin—liver cancer	0.000227	0.000528	CcSEcCtD
Paroxetine—Back pain—Epirubicin—liver cancer	0.000227	0.000526	CcSEcCtD
Paroxetine—Angiopathy—Doxorubicin—liver cancer	0.000226	0.000524	CcSEcCtD
Paroxetine—Muscle spasms—Epirubicin—liver cancer	0.000225	0.000523	CcSEcCtD
Paroxetine—Immune system disorder—Doxorubicin—liver cancer	0.000225	0.000522	CcSEcCtD
Paroxetine—Mediastinal disorder—Doxorubicin—liver cancer	0.000224	0.000521	CcSEcCtD
Paroxetine—Chills—Doxorubicin—liver cancer	0.000223	0.000519	CcSEcCtD
Paroxetine—Arrhythmia—Doxorubicin—liver cancer	0.000222	0.000516	CcSEcCtD
Paroxetine—Vision blurred—Epirubicin—liver cancer	0.000221	0.000512	CcSEcCtD
Paroxetine—Alopecia—Doxorubicin—liver cancer	0.00022	0.000511	CcSEcCtD
Paroxetine—Mental disorder—Doxorubicin—liver cancer	0.000218	0.000506	CcSEcCtD
Paroxetine—Ill-defined disorder—Epirubicin—liver cancer	0.000217	0.000505	CcSEcCtD
Paroxetine—Malnutrition—Doxorubicin—liver cancer	0.000217	0.000503	CcSEcCtD
Paroxetine—Erythema—Doxorubicin—liver cancer	0.000217	0.000503	CcSEcCtD
Paroxetine—Anaemia—Epirubicin—liver cancer	0.000216	0.000503	CcSEcCtD
Paroxetine—Agitation—Epirubicin—liver cancer	0.000215	0.0005	CcSEcCtD
Paroxetine—Flatulence—Doxorubicin—liver cancer	0.000214	0.000496	CcSEcCtD
Paroxetine—Tension—Doxorubicin—liver cancer	0.000213	0.000494	CcSEcCtD
Paroxetine—Dysgeusia—Doxorubicin—liver cancer	0.000212	0.000493	CcSEcCtD
Paroxetine—Malaise—Epirubicin—liver cancer	0.000211	0.00049	CcSEcCtD
Paroxetine—Nervousness—Doxorubicin—liver cancer	0.00021	0.000489	CcSEcCtD
Paroxetine—Vertigo—Epirubicin—liver cancer	0.00021	0.000489	CcSEcCtD
Paroxetine—Syncope—Epirubicin—liver cancer	0.00021	0.000488	CcSEcCtD
Paroxetine—Leukopenia—Epirubicin—liver cancer	0.00021	0.000487	CcSEcCtD
Paroxetine—Back pain—Doxorubicin—liver cancer	0.00021	0.000487	CcSEcCtD
Paroxetine—Muscle spasms—Doxorubicin—liver cancer	0.000208	0.000484	CcSEcCtD
Paroxetine—Palpitations—Epirubicin—liver cancer	0.000207	0.000481	CcSEcCtD
Paroxetine—Loss of consciousness—Epirubicin—liver cancer	0.000206	0.000478	CcSEcCtD
Paroxetine—Cough—Epirubicin—liver cancer	0.000204	0.000475	CcSEcCtD
Paroxetine—Vision blurred—Doxorubicin—liver cancer	0.000204	0.000474	CcSEcCtD
Paroxetine—Convulsion—Epirubicin—liver cancer	0.000203	0.000471	CcSEcCtD
Paroxetine—Hypertension—Epirubicin—liver cancer	0.000202	0.000469	CcSEcCtD
Paroxetine—Ill-defined disorder—Doxorubicin—liver cancer	0.000201	0.000467	CcSEcCtD
Paroxetine—Anaemia—Doxorubicin—liver cancer	0.0002	0.000465	CcSEcCtD
Paroxetine—Chest pain—Epirubicin—liver cancer	0.000199	0.000463	CcSEcCtD
Paroxetine—Myalgia—Epirubicin—liver cancer	0.000199	0.000463	CcSEcCtD
Paroxetine—Arthralgia—Epirubicin—liver cancer	0.000199	0.000463	CcSEcCtD
Paroxetine—Agitation—Doxorubicin—liver cancer	0.000199	0.000462	CcSEcCtD
Paroxetine—Anxiety—Epirubicin—liver cancer	0.000199	0.000461	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000198	0.00046	CcSEcCtD
Paroxetine—Discomfort—Epirubicin—liver cancer	0.000197	0.000457	CcSEcCtD
Paroxetine—Malaise—Doxorubicin—liver cancer	0.000195	0.000454	CcSEcCtD
Paroxetine—Dry mouth—Epirubicin—liver cancer	0.000195	0.000453	CcSEcCtD
Paroxetine—Vertigo—Doxorubicin—liver cancer	0.000195	0.000452	CcSEcCtD
Paroxetine—Syncope—Doxorubicin—liver cancer	0.000194	0.000451	CcSEcCtD
Paroxetine—Leukopenia—Doxorubicin—liver cancer	0.000194	0.00045	CcSEcCtD
Paroxetine—Confusional state—Epirubicin—liver cancer	0.000193	0.000447	CcSEcCtD
Paroxetine—Palpitations—Doxorubicin—liver cancer	0.000191	0.000445	CcSEcCtD
Paroxetine—Oedema—Epirubicin—liver cancer	0.000191	0.000444	CcSEcCtD
Paroxetine—Anaphylactic shock—Epirubicin—liver cancer	0.000191	0.000444	CcSEcCtD
Paroxetine—Loss of consciousness—Doxorubicin—liver cancer	0.00019	0.000442	CcSEcCtD
Paroxetine—Infection—Epirubicin—liver cancer	0.00019	0.000441	CcSEcCtD
Paroxetine—Cough—Doxorubicin—liver cancer	0.000189	0.000439	CcSEcCtD
Paroxetine—Shock—Epirubicin—liver cancer	0.000188	0.000437	CcSEcCtD
Paroxetine—Convulsion—Doxorubicin—liver cancer	0.000188	0.000436	CcSEcCtD
Paroxetine—Nervous system disorder—Epirubicin—liver cancer	0.000187	0.000435	CcSEcCtD
Paroxetine—Thrombocytopenia—Epirubicin—liver cancer	0.000187	0.000435	CcSEcCtD
Paroxetine—Hypertension—Doxorubicin—liver cancer	0.000187	0.000434	CcSEcCtD
Paroxetine—Tachycardia—Epirubicin—liver cancer	0.000187	0.000433	CcSEcCtD
Paroxetine—Skin disorder—Epirubicin—liver cancer	0.000186	0.000431	CcSEcCtD
Paroxetine—Hyperhidrosis—Epirubicin—liver cancer	0.000185	0.000429	CcSEcCtD
Paroxetine—Chest pain—Doxorubicin—liver cancer	0.000184	0.000428	CcSEcCtD
Paroxetine—Myalgia—Doxorubicin—liver cancer	0.000184	0.000428	CcSEcCtD
Paroxetine—Arthralgia—Doxorubicin—liver cancer	0.000184	0.000428	CcSEcCtD
Paroxetine—Anxiety—Doxorubicin—liver cancer	0.000184	0.000427	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000183	0.000425	CcSEcCtD
Paroxetine—Discomfort—Doxorubicin—liver cancer	0.000182	0.000423	CcSEcCtD
Paroxetine—Dry mouth—Doxorubicin—liver cancer	0.00018	0.000419	CcSEcCtD
Paroxetine—Hypotension—Epirubicin—liver cancer	0.000179	0.000415	CcSEcCtD
Paroxetine—Confusional state—Doxorubicin—liver cancer	0.000178	0.000414	CcSEcCtD
Paroxetine—Oedema—Doxorubicin—liver cancer	0.000177	0.000411	CcSEcCtD
Paroxetine—Anaphylactic shock—Doxorubicin—liver cancer	0.000177	0.000411	CcSEcCtD
Paroxetine—Infection—Doxorubicin—liver cancer	0.000176	0.000408	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000174	0.000404	CcSEcCtD
Paroxetine—Shock—Doxorubicin—liver cancer	0.000174	0.000404	CcSEcCtD
Paroxetine—Nervous system disorder—Doxorubicin—liver cancer	0.000173	0.000403	CcSEcCtD
Paroxetine—Thrombocytopenia—Doxorubicin—liver cancer	0.000173	0.000402	CcSEcCtD
Paroxetine—Insomnia—Epirubicin—liver cancer	0.000173	0.000401	CcSEcCtD
Paroxetine—Tachycardia—Doxorubicin—liver cancer	0.000173	0.000401	CcSEcCtD
Paroxetine—Skin disorder—Doxorubicin—liver cancer	0.000172	0.000399	CcSEcCtD
Paroxetine—Paraesthesia—Epirubicin—liver cancer	0.000172	0.000399	CcSEcCtD
Paroxetine—Hyperhidrosis—Doxorubicin—liver cancer	0.000171	0.000397	CcSEcCtD
Paroxetine—Dyspnoea—Epirubicin—liver cancer	0.00017	0.000396	CcSEcCtD
Paroxetine—Somnolence—Epirubicin—liver cancer	0.00017	0.000395	CcSEcCtD
Paroxetine—Dyspepsia—Epirubicin—liver cancer	0.000168	0.000391	CcSEcCtD
Paroxetine—Decreased appetite—Epirubicin—liver cancer	0.000166	0.000386	CcSEcCtD
Paroxetine—Hypotension—Doxorubicin—liver cancer	0.000165	0.000384	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000165	0.000383	CcSEcCtD
Paroxetine—Fatigue—Epirubicin—liver cancer	0.000165	0.000383	CcSEcCtD
Paroxetine—Constipation—Epirubicin—liver cancer	0.000163	0.00038	CcSEcCtD
Paroxetine—Pain—Epirubicin—liver cancer	0.000163	0.00038	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000161	0.000374	CcSEcCtD
Paroxetine—Insomnia—Doxorubicin—liver cancer	0.00016	0.000371	CcSEcCtD
Paroxetine—Paraesthesia—Doxorubicin—liver cancer	0.000159	0.000369	CcSEcCtD
Paroxetine—Dyspnoea—Doxorubicin—liver cancer	0.000158	0.000366	CcSEcCtD
Paroxetine—Feeling abnormal—Epirubicin—liver cancer	0.000157	0.000366	CcSEcCtD
Paroxetine—Somnolence—Doxorubicin—liver cancer	0.000157	0.000365	CcSEcCtD
Paroxetine—Gastrointestinal pain—Epirubicin—liver cancer	0.000156	0.000363	CcSEcCtD
Paroxetine—Dyspepsia—Doxorubicin—liver cancer	0.000156	0.000361	CcSEcCtD
Paroxetine—Decreased appetite—Doxorubicin—liver cancer	0.000154	0.000357	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000153	0.000355	CcSEcCtD
Paroxetine—Fatigue—Doxorubicin—liver cancer	0.000152	0.000354	CcSEcCtD
Paroxetine—Urticaria—Epirubicin—liver cancer	0.000152	0.000353	CcSEcCtD
Paroxetine—Constipation—Doxorubicin—liver cancer	0.000151	0.000351	CcSEcCtD
Paroxetine—Pain—Doxorubicin—liver cancer	0.000151	0.000351	CcSEcCtD
Paroxetine—Body temperature increased—Epirubicin—liver cancer	0.000151	0.000351	CcSEcCtD
Paroxetine—Abdominal pain—Epirubicin—liver cancer	0.000151	0.000351	CcSEcCtD
Paroxetine—Feeling abnormal—Doxorubicin—liver cancer	0.000146	0.000338	CcSEcCtD
Paroxetine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000145	0.000336	CcSEcCtD
Paroxetine—Hypersensitivity—Epirubicin—liver cancer	0.000141	0.000327	CcSEcCtD
Paroxetine—Urticaria—Doxorubicin—liver cancer	0.00014	0.000326	CcSEcCtD
Paroxetine—Abdominal pain—Doxorubicin—liver cancer	0.00014	0.000325	CcSEcCtD
Paroxetine—Body temperature increased—Doxorubicin—liver cancer	0.00014	0.000325	CcSEcCtD
Paroxetine—Asthenia—Epirubicin—liver cancer	0.000137	0.000318	CcSEcCtD
Paroxetine—Pruritus—Epirubicin—liver cancer	0.000135	0.000314	CcSEcCtD
Paroxetine—Diarrhoea—Epirubicin—liver cancer	0.000131	0.000304	CcSEcCtD
Paroxetine—Hypersensitivity—Doxorubicin—liver cancer	0.00013	0.000303	CcSEcCtD
Paroxetine—Asthenia—Doxorubicin—liver cancer	0.000127	0.000295	CcSEcCtD
Paroxetine—Dizziness—Epirubicin—liver cancer	0.000126	0.000293	CcSEcCtD
Paroxetine—Pruritus—Doxorubicin—liver cancer	0.000125	0.000291	CcSEcCtD
Paroxetine—Vomiting—Epirubicin—liver cancer	0.000122	0.000282	CcSEcCtD
Paroxetine—Diarrhoea—Doxorubicin—liver cancer	0.000121	0.000281	CcSEcCtD
Paroxetine—Rash—Epirubicin—liver cancer	0.000121	0.00028	CcSEcCtD
Paroxetine—Dermatitis—Epirubicin—liver cancer	0.00012	0.00028	CcSEcCtD
Paroxetine—Headache—Epirubicin—liver cancer	0.00012	0.000278	CcSEcCtD
Paroxetine—Dizziness—Doxorubicin—liver cancer	0.000117	0.000272	CcSEcCtD
Paroxetine—Nausea—Epirubicin—liver cancer	0.000114	0.000264	CcSEcCtD
Paroxetine—Vomiting—Doxorubicin—liver cancer	0.000112	0.000261	CcSEcCtD
Paroxetine—Rash—Doxorubicin—liver cancer	0.000111	0.000259	CcSEcCtD
Paroxetine—Dermatitis—Doxorubicin—liver cancer	0.000111	0.000259	CcSEcCtD
Paroxetine—Headache—Doxorubicin—liver cancer	0.000111	0.000257	CcSEcCtD
Paroxetine—Nausea—Doxorubicin—liver cancer	0.000105	0.000244	CcSEcCtD
Paroxetine—CHRM4—Signaling Pathways—CDKN1B—liver cancer	1.44e-05	9.41e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK14—liver cancer	1.44e-05	9.39e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ESR1—liver cancer	1.43e-05	9.38e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ESR1—liver cancer	1.43e-05	9.33e-05	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—liver cancer	1.42e-05	9.31e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ESR1—liver cancer	1.42e-05	9.3e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—F2—liver cancer	1.42e-05	9.27e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CD—liver cancer	1.41e-05	9.25e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CASP3—liver cancer	1.41e-05	9.22e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—F2—liver cancer	1.41e-05	9.22e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTP1—liver cancer	1.41e-05	9.22e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ESR1—liver cancer	1.41e-05	9.21e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL2—liver cancer	1.41e-05	9.21e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—F2—liver cancer	1.4e-05	9.19e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HRAS—liver cancer	1.4e-05	9.17e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—liver cancer	1.4e-05	9.16e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTP1—liver cancer	1.4e-05	9.14e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ALB—liver cancer	1.39e-05	9.13e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MTHFR—liver cancer	1.39e-05	9.12e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—F2—liver cancer	1.39e-05	9.1e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—HMOX1—liver cancer	1.39e-05	9.09e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CG—liver cancer	1.38e-05	9.05e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—HMOX1—liver cancer	1.38e-05	9.01e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDKN1B—liver cancer	1.38e-05	9.01e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTM1—liver cancer	1.37e-05	8.99e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCND1—liver cancer	1.37e-05	8.98e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—JUN—liver cancer	1.37e-05	8.96e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARA—liver cancer	1.37e-05	8.94e-05	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—liver cancer	1.36e-05	8.91e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CTNNB1—liver cancer	1.36e-05	8.89e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CG—liver cancer	1.36e-05	8.87e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APC—liver cancer	1.36e-05	8.87e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CASP3—liver cancer	1.35e-05	8.83e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APC—liver cancer	1.35e-05	8.82e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CG—liver cancer	1.35e-05	8.82e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL2—liver cancer	1.35e-05	8.82e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APC—liver cancer	1.34e-05	8.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CG—liver cancer	1.34e-05	8.79e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—liver cancer	1.34e-05	8.77e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARG—liver cancer	1.33e-05	8.73e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—liver cancer	1.33e-05	8.71e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CG—liver cancer	1.33e-05	8.71e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APC—liver cancer	1.33e-05	8.71e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CDKN1A—liver cancer	1.33e-05	8.68e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCND1—liver cancer	1.31e-05	8.59e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—JUN—liver cancer	1.31e-05	8.58e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP1A1—liver cancer	1.3e-05	8.52e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CTNNB1—liver cancer	1.3e-05	8.51e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK8—liver cancer	1.3e-05	8.47e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTM1—liver cancer	1.29e-05	8.47e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—liver cancer	1.29e-05	8.45e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTM1—liver cancer	1.28e-05	8.4e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—liver cancer	1.28e-05	8.34e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—BRAF—liver cancer	1.27e-05	8.34e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDKN1A—liver cancer	1.27e-05	8.31e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—BRAF—liver cancer	1.27e-05	8.29e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—BRAF—liver cancer	1.26e-05	8.27e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BRAF—liver cancer	1.25e-05	8.19e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK8—liver cancer	1.24e-05	8.12e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—liver cancer	1.24e-05	8.09e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CB—liver cancer	1.23e-05	8.06e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.23e-05	8.03e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP1A1—liver cancer	1.23e-05	8.03e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP1A1—liver cancer	1.22e-05	7.96e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CD—liver cancer	1.22e-05	7.95e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MTHFR—liver cancer	1.21e-05	7.94e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ALB—liver cancer	1.2e-05	7.85e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—liver cancer	1.2e-05	7.82e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CD—liver cancer	1.19e-05	7.8e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARA—liver cancer	1.19e-05	7.79e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CD—liver cancer	1.19e-05	7.76e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—STAT3—liver cancer	1.18e-05	7.75e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CD—liver cancer	1.18e-05	7.73e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PIK3CA—liver cancer	1.18e-05	7.72e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SERPINE1—liver cancer	1.18e-05	7.71e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PIK3CA—liver cancer	1.17e-05	7.68e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SERPINE1—liver cancer	1.17e-05	7.67e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CG—liver cancer	1.17e-05	7.66e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PIK3CA—liver cancer	1.17e-05	7.66e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CD—liver cancer	1.17e-05	7.66e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SERPINE1—liver cancer	1.17e-05	7.65e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—liver cancer	1.17e-05	7.63e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—liver cancer	1.16e-05	7.59e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PIK3CA—liver cancer	1.16e-05	7.58e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SERPINE1—liver cancer	1.16e-05	7.57e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—liver cancer	1.16e-05	7.57e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—liver cancer	1.15e-05	7.49e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—liver cancer	1.15e-05	7.49e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MTHFR—liver cancer	1.14e-05	7.48e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MTHFR—liver cancer	1.13e-05	7.42e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—STAT3—liver cancer	1.13e-05	7.42e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARG—liver cancer	1.13e-05	7.39e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARA—liver cancer	1.12e-05	7.34e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARA—liver cancer	1.11e-05	7.28e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—liver cancer	1.1e-05	7.2e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—liver cancer	1.1e-05	7.18e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	1.07e-05	7.01e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PIK3CA—liver cancer	1.07e-05	6.98e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RAF1—liver cancer	1.06e-05	6.96e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PIK3CA—liver cancer	1.06e-05	6.95e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CB—liver cancer	1.06e-05	6.93e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RAF1—liver cancer	1.06e-05	6.92e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RAF1—liver cancer	1.05e-05	6.9e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—liver cancer	1.05e-05	6.89e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PIK3CA—liver cancer	1.05e-05	6.89e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—liver cancer	1.05e-05	6.88e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RAF1—liver cancer	1.04e-05	6.83e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MTOR—liver cancer	1.04e-05	6.8e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CB—liver cancer	1.04e-05	6.8e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CB—liver cancer	1.03e-05	6.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MTOR—liver cancer	1.03e-05	6.76e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CB—liver cancer	1.03e-05	6.74e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MTOR—liver cancer	1.03e-05	6.74e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CD—liver cancer	1.03e-05	6.73e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CG—liver cancer	1.02e-05	6.67e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MTOR—liver cancer	1.02e-05	6.67e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CB—liver cancer	1.02e-05	6.67e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—liver cancer	1.02e-05	6.65e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ALB—liver cancer	1.02e-05	6.65e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	9.99e-06	6.54e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—liver cancer	9.92e-06	6.49e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—liver cancer	9.86e-06	6.45e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARG—liver cancer	9.84e-06	6.44e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—liver cancer	9.83e-06	6.43e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1B—liver cancer	9.75e-06	6.38e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—liver cancer	9.74e-06	6.37e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—liver cancer	9.74e-06	6.37e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1B—liver cancer	9.7e-06	6.34e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1B—liver cancer	9.66e-06	6.32e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—liver cancer	9.64e-06	6.31e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CG—liver cancer	9.61e-06	6.29e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—liver cancer	9.59e-06	6.28e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1B—liver cancer	9.57e-06	6.26e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—liver cancer	9.56e-06	6.26e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—liver cancer	9.55e-06	6.25e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2—liver cancer	9.54e-06	6.24e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CG—liver cancer	9.53e-06	6.23e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—liver cancer	9.5e-06	6.22e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—liver cancer	9.49e-06	6.21e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2—liver cancer	9.49e-06	6.21e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—liver cancer	9.47e-06	6.2e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—liver cancer	9.47e-06	6.19e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2—liver cancer	9.46e-06	6.19e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—liver cancer	9.44e-06	6.18e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—liver cancer	9.41e-06	6.16e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—liver cancer	9.38e-06	6.14e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2—liver cancer	9.37e-06	6.13e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PIK3CA—liver cancer	9.34e-06	6.11e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—liver cancer	9.32e-06	6.1e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCND1—liver cancer	9.3e-06	6.08e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—JUN—liver cancer	9.28e-06	6.07e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARG—liver cancer	9.28e-06	6.07e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCND1—liver cancer	9.25e-06	6.05e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—JUN—liver cancer	9.23e-06	6.04e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCND1—liver cancer	9.22e-06	6.03e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CTNNB1—liver cancer	9.21e-06	6.03e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—JUN—liver cancer	9.2e-06	6.02e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARG—liver cancer	9.2e-06	6.02e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CTNNB1—liver cancer	9.16e-06	5.99e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCND1—liver cancer	9.13e-06	5.97e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CTNNB1—liver cancer	9.13e-06	5.97e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—JUN—liver cancer	9.11e-06	5.96e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CTNNB1—liver cancer	9.04e-06	5.92e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—liver cancer	9.04e-06	5.91e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—liver cancer	9.03e-06	5.91e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1A—liver cancer	9e-06	5.89e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—liver cancer	8.98e-06	5.88e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CB—liver cancer	8.97e-06	5.87e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CD—liver cancer	8.97e-06	5.87e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—liver cancer	8.95e-06	5.86e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1A—liver cancer	8.95e-06	5.85e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CA—liver cancer	8.94e-06	5.85e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1A—liver cancer	8.92e-06	5.84e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—liver cancer	8.86e-06	5.8e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALB—liver cancer	8.85e-06	5.79e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1A—liver cancer	8.83e-06	5.78e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK8—liver cancer	8.78e-06	5.74e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—liver cancer	8.76e-06	5.73e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK8—liver cancer	8.73e-06	5.71e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—liver cancer	8.71e-06	5.7e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK8—liver cancer	8.71e-06	5.7e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—liver cancer	8.68e-06	5.68e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—liver cancer	8.65e-06	5.66e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—liver cancer	8.64e-06	5.65e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK8—liver cancer	8.62e-06	5.64e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—liver cancer	8.6e-06	5.63e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CD—liver cancer	8.45e-06	5.53e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CD—liver cancer	8.38e-06	5.48e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALB—liver cancer	8.34e-06	5.46e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—liver cancer	8.28e-06	5.41e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—liver cancer	8.27e-06	5.41e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALB—liver cancer	8.27e-06	5.41e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—liver cancer	8.11e-06	5.3e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—liver cancer	8.06e-06	5.28e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—liver cancer	8.04e-06	5.26e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT3—liver cancer	8.03e-06	5.25e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT3—liver cancer	7.98e-06	5.22e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—liver cancer	7.96e-06	5.21e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT3—liver cancer	7.96e-06	5.21e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—liver cancer	7.92e-06	5.18e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT3—liver cancer	7.88e-06	5.16e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CB—liver cancer	7.81e-06	5.11e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—liver cancer	7.63e-06	4.99e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CA—liver cancer	7.51e-06	4.91e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—liver cancer	7.46e-06	4.88e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—liver cancer	7.44e-06	4.87e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—liver cancer	7.42e-06	4.85e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—liver cancer	7.4e-06	4.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—liver cancer	7.4e-06	4.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—liver cancer	7.38e-06	4.83e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CB—liver cancer	7.36e-06	4.82e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—liver cancer	7.32e-06	4.79e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—liver cancer	7.31e-06	4.78e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—liver cancer	7.31e-06	4.78e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CB—liver cancer	7.3e-06	4.78e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—liver cancer	6.89e-06	4.51e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—liver cancer	6.86e-06	4.49e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—liver cancer	6.83e-06	4.47e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—liver cancer	6.77e-06	4.43e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CA—liver cancer	6.46e-06	4.23e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CA—liver cancer	6.33e-06	4.14e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CA—liver cancer	6.3e-06	4.12e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CA—liver cancer	6.28e-06	4.11e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CA—liver cancer	6.22e-06	4.07e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—liver cancer	6.13e-06	4.01e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—liver cancer	6.13e-06	4.01e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—liver cancer	6.09e-06	3.99e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—liver cancer	6.07e-06	3.97e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—liver cancer	6.01e-06	3.94e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—liver cancer	5.86e-06	3.83e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—liver cancer	5.83e-06	3.81e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—liver cancer	5.81e-06	3.8e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—liver cancer	5.75e-06	3.76e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—liver cancer	5.61e-06	3.67e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—liver cancer	5.58e-06	3.65e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—liver cancer	5.56e-06	3.64e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—liver cancer	5.51e-06	3.6e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CA—liver cancer	5.47e-06	3.58e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—liver cancer	5.28e-06	3.45e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—liver cancer	5.17e-06	3.38e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—liver cancer	5.14e-06	3.37e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—liver cancer	5.13e-06	3.36e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—liver cancer	5.08e-06	3.32e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CA—liver cancer	4.76e-06	3.12e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CA—liver cancer	4.49e-06	2.94e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—liver cancer	4.47e-06	2.92e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CA—liver cancer	4.45e-06	2.91e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—liver cancer	3.89e-06	2.55e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—liver cancer	3.67e-06	2.4e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—liver cancer	3.64e-06	2.38e-05	CbGpPWpGaD
